Back to Top Skip to main content

DOD participates in new COVID-19 antibody combination prevention trial

Woman gets blood drawn Miranda Heilweil gets her blood drawn at Madigan Army Medical Center, Washington, one of five DOD sites where the STORM CHASER trial is studying the efficacy of an antibody product that could prevent COVID-19 in people who have been exposed to the virus within eight days. (U.S. Army photo by Janell Cain)

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts

While the Military Health System continues to support the development and distribution of COVID-19 vaccines to counter the ongoing public health threat of the disease, it’s investing in other efforts to counter the SARS-CoV-2 virus.

One of those includes evolving therapeutics as part of the U.S. government’s COVID-19 response through clinical trials of a long-acting antibody combination medicine to prevent COVID-19 among people who have been exposed to the disease.

The intramuscular long-acting antibody product, called AZD7442 and developed by AstraZeneca, is undergoing a phase III clinical trial at five Department of Defense sites to study its efficacy among eligible MHS beneficiaries who have recently been exposed to others with SARS-CoV-2 infection.

“This study will run for one year, although interim and primary analyses will likely occur much earlier in 2021,” said Dr. Simon Pollett, associate scientific director and COVID-19 research area director at the Uniformed Services University of the Health Science’s (USU) Infectious Diseases Clinical Research Program (IDCRP).

Under the name STORM CHASER, Pollett’s program is coordinating teams of physicians, nurses, pharmacists, and clinical research staff at Tripler Army Medical Center in Hawaii, Madigan Army Medical Center in Washington, William Beaumont Army Medical Center in Texas, Naval Medical Center Portsmouth in Virginia, and USU in Maryland. The lead investigators at these sites are Army Col. Viseth Ngauy, Army Col. Anjali Kunz, Dr. Gina Kubicz, Navy Lt. Cmdr. Tida Lee, and Army Lt. Col. Jeffrey Livezey, respectively.

This study is designed to prevent the development of illness in people who have been exposed to COVID-19 in care homes and sites with enhanced risk of disease transmission, under the sponsorship of AstraZeneca with support from the U.S. health information technology and clinical research firm IQVIA. IDCRP is supported through a cooperative agreement with The Henry M. Jackson Foundation for the Advancement of Military Medicine.

Primarily, STORM CHASER seeks to determine if the antibody injection can prevent COVID-19 in people who were exposed to the SARS-CoV-2 virus – which causes the disease – within the last eight days, but have not yet developed symptoms, explained Pollett. “This may include those exposed by household contacts, in crowded working conditions, in health care settings, and other scenarios,” he added.

A secondary objective of the study is examining whether the antibody injection can reduce viral shedding in those who may develop the disease after receiving the injection, said Pollett. Viral shedding occurs when the virus replicates inside the body and is released to the environment, making the host person contagious to others.

“Reduced viral shedding may perhaps correlate with reduced transmissibility, but this requires further study,” said Pollett.

STORM CHASER also aims to see if individuals who receive the AZD7442 injection after SARS-CoV-2 exposure experience less severe symptoms of COVID-19. Likewise, the clinical trial seeks to explore “sequencing of breakthrough virus to look at antibody escape mutations,” said Navy Capt. Timothy Burgess, IDRCP director. This will help determine whether AZD7442 protects across a range of SARS-CoV-2 strains, including newly emerged variants.

AZD7442 contains infection-fighting proteins called monoclonal antibodies that work to neutralize the virus, thus preventing COVID-19. Each dose is given once as two intramuscular shots in each gluteal region, within eight days of exposure.

If clinical trials are successful and the product receives emergency use authorization from the Food and Drug Administration, this investigational product would become another tool to defeat the COVID-19 pandemic. Two vaccines, by Pfizer-BioNTech and Moderna, are available to the U.S. population older than 16 and 18 years of age, respectively, under FDA’s EUA, with three more vaccines, including AstraZeneca’s, currently in clinical trials.

The vaccines work inside the body by triggering the immune system to make antibodies that will block or kill the SARS-CoV-2 spike protein if it enters the body, which results in immunity to coronavirus. They are given to healthy individuals who have not been exposed to the virus to protect them against getting seriously ill from the disease if they become infected or exposed, and studies are still being conducted to gauge their ability to keep people from spreading the virus.

AZD7442 may provide very rapid protection against COVID-19 in individuals who have been exposed because it is given while the virus is incubating, said Burgess. But those who have already received the COVID-19 vaccine are not eligible to participate in the study.

“The investigational product is intended to provide rapid immunity after exposure, with up to six months of protection thereafter,” said Burgess. “STORM CHASER is examining the efficacy of this.”

If the study is successful in achieving its objective of preventing COVID-19 after exposure, the hope, according to Pollett, is that transmission chains will also be stopped by preventing such COVID-19 cases, but further study is required.

This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority in partnership with the Department of Defense; Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense; under Contract No. W911QY-21-9-0001.

If interested in participating in the STORM CHASER trial - please contact Julia Rozman at: julia.rozman.ctr@usuhs.edu.

You also may be interested in...

Appenzeller emphasizes: Get COVID-19 vaccine, no matter where

Article
4/16/2021
Military personnel explaining forensic equipment

The DHA’s Combat Support assistant director had some direct and encouraging words about the military’s COVID-19 vaccine rollout to date.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Toolkit

Got Your 6 - April 16, 2021

Video
4/16/2021
Got Your 6 - April 16, 2021

"Got Your 6" is TRICARE's COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

COVID-19 Toolkit | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Tele-critical care will play increased COVID-19 response role in 2021

Article
4/15/2021
Infographic that says "202 tele-critical care successes will help 2021 COVID19 response"

Virtual health and particularly tele-critical care for critically ill patients assumed frontline roles in sustaining care while keeping beneficiaries and health care teams safe.

Recommended Content:

COVID-19 Toolkit | Coronavirus | MHS Transformation

Join Us!! Third COVID-19 Townhall Update with Major General George Appenzeller!

Article
4/13/2021
MHS and Military OneSource COVID-19 Townhall, with Major General (Dr.) George N. Appenzeller.  Wednesday, 14 April, 1 PM ET

Join us for the MHS' Third COVID-19 Townhall with Major General George Appenzeller

Recommended Content:

Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

DOD surpasses 2 million COVID-19 vaccines worldwide

Article
4/9/2021
Military health personnel wearing a face mask and a face shield giving the COVID-19 vaccine

The DOD hit the 2 million mark for vaccinations worldwide just a month after the 1 million milestone.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Public health remains an integral part in the fight against COVID

Article
4/9/2021
Infographic featuring health personnel wearing face shields and mask with "National Public Health Week" across the top of the picture

The pandemic has highlighted a need to provide more advanced training on infection prevention and control.

Recommended Content:

COVID-19 Toolkit | April Toolkit | Public Health | Coronavirus | COVID-19 Vaccine Toolkit

Got Your 6 - April 6, 2021

Video
4/6/2021
Image of soldier for the April 6, 2021 "Got Your Six" video

"Got Your 6" is TRICARE's COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

COVID-19 Toolkit | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Children’s well-being contributes immeasurably to force readiness

Article
4/6/2021
Military personnel wearing face mask in the back of a truck

The Defense Health Agency joins in celebrating military children during Month of the Military Child, observed in April, and always.

Recommended Content:

Children's Health | April Toolkit | Month of the Military Child – Celebrating the Mighty | Coronavirus | Month of the Military Child | Month of the Military Child Image Library

Telemedicine advances put to the test during pandemic

Article
4/1/2021
Uniformed service member stands behind wall of computer screens

COVID-19 has led to the need for physical distancing and has overwhelmed the capacities of health systems, compelling many to adopt telehealth solutions.

Recommended Content:

Technology | Research and Innovation | Coronavirus | COVID-19 Vaccine Toolkit

DOD healthcare leaders give COVID-19 update, praise DHA personnel

Article
3/30/2021
Picture of Director Army Lt. Gen. (Dr. Ronald Place providing a COVID-19 update at  the Pentagon

Dr. Terry Adirim and Army Lt. Gen. (Dr.) Ronald Place provide update on COVID-19 vaccination progress and offer thanks to MHS workers for their contributions.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Lovell FHCC staff steps up to create formidable COVID-19 team

Article
3/30/2021
Military health personnel preparing to administer the COVID-19 vaccine

The COVID-19 vaccination effort at the Capt. James A. Lovell Federal Health Care Center in North Chicago, Illinois, has brought out the best in staff.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

Dover Air Force Base features ‘Park ‘N Pickup’ pharmacy

Article
3/26/2021
Picture of prescription sitting on a counter

Due to the increased need for patient safety, the 436th Medical Group pharmacy at Dover Air Force Base has implemented a Park ‘N Pickup process.

Recommended Content:

Patient Safety Awareness Week | COVID-19 Toolkit | Coronavirus | Patient Safety

Got Your 6 - March 26, 2021

Video
3/26/2021
Got Your 6 - March 26, 2021

"Got Your 6" is TRICARE's COVID-19 vaccine video series that delivers important information and updates, three times a month. It includes the latest information about DoD vaccine distribution, the TRICARE health benefit, and vaccine availability for a DoD-affiliated, and TRICARE beneficiary audience.

Recommended Content:

COVID-19 Toolkit | COVID-19 Vaccine Efforts | COVID-19 Vaccine Toolkit

DHA Form 207: COVID-19 Vaccine Screening and Immunization Document

Form/Template
3/25/2021

The purpose of this form is to determine if the COVID-19 vaccine can be administered to the patient.

Recommended Content:

COVID-19 Toolkit | Coronavirus | COVID-19 Vaccine Efforts

TAB A MEO COVID19 Medical Coding Policy

Policy

Memorandum for DHA Staff - Military Medical Treatment Facilities to Implement Updated DHA COVID-19 Medical Coding Policy

  • Identification #: N/A
  • Date: 3/25/2021
  • Type: Memorandums
  • Topics: Coronavirus
<< < 1 2 3 4 5  ... > >> 
Showing results 1 - 15 Page 1 of 30

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.